The price of hesitation

European governments navigate an ever more competitive global landscape, stagnating productivity and competing demands on budgets. We have successfully faced and solved many challenges in the past, but this situation is different: the choices we make today will shape our health​ ​care systems and patient care, and these choices will dictate Europe’s economic performance and global relevance for decades to come.

For those of us in the life sciences, these aren’t just macroeconomic trends — they are the pulse of a system that determines how quickly a breakthrough reaches a patient. It is a high-stakes environment where policies on health​ ​care and innovation carry urgent human and economic consequences. When a medicine has the power to treat or potentially cure, neither innovators nor policymakers want to drag their heels, because no person requiring health​ ​care can afford the luxury of delay.

The true economic burden of health​ ​care isn’t financing health innovation, but the cost of failing to do so.

Europe’s challenge is clear: we must better align our industrial strength in life science with public health goals, ensuring innovation reaches both patients and economies faster. The question is no longer what Europe ​wants​ to be — it is where Europe ​chooses​ to invest to remain a global player.

Health as ​​e​​​​conomic ​​i​​​​nfrastructure

Under the weight of mounting budget pressures, it is understandable that governments often view health primarily as a cost to be contained. However, this perspective is disconnected from modern economic reality.

And let me be clear: ​ ​the true economic burden of health​ ​care isn’t financing health innovation, but the cost of failing to do so. For years, Europe has already been paying the price of lost productivity: citizens forced out of the workforce too early and chronic diseases managed too late. For instance, cardiovascular diseases alone cost the E​​uropean ​​U​nion​ economy up to €282 billion annually. This creates a massive​​ yet avoidable strain on national budgets, especially as pharmaceutical innovation is estimated to be responsible for up to two-thirds of life expectancy gains in high-income countries​.​¹

Every medical breakthrough that enables a citizen to return to work or care for their family is a direct investment in Europe’s economic strength.

We must shift our mindset​​.​​​​ ​​H​​​​ealth is not merely a social good; it is economic infrastructure. Healthier societies are inherently more productive and resilient, and ​ ​every medical breakthrough that enables a citizen to return to work or care for their family is a direct investment in Europe’s economic strength. Investing in innovation today is the only way to secure a competitive workforce and reduce long-term systemic costs.

The ​​c​​​​ompetitiveness ​​t​​​​est: ​​a​​​​ ​​s​​​​trategic ​​a​​​​sset, ​​n​​​​ot a ​​l​​​​ine ​​i​​​​tem

Europe’s life sciences sector is one of the few remaining areas ​​that ​​​​​​retains genuine global competitiveness and strength, contributing​ more than​ €300​​ billion to ​​annual output and supporting 2 million high-skilled jobs across ​​m​​​​ember ​​s​​​​tates​.​²​​ It anchors Europe’s trade resilience, generating a trade surplus 66​​ percent​​​​ higher than all other EU sectors combined​.​³​​

But the warning signs are clear: while Europe still accounts for 20​​ percent​​​​ of global pharmaceutical ​​research and development​​​​​​, its share of global investment is shrinking as capital and talent migrate​​ elsewhere​.​⁴​​ Europe’s world-class science is being held back by fragmentation and regulatory inertia.

We must treat this sector as a pillar of our sovereignty and a strategic asset, not merely a cost to be managed.

If we want to lead the next wave of medical breakthroughs, we must move at the speed of global change. This requires a fundamental shift: simplifying clinical trial regulations, deploying AI-driven digital tools, incentivizing research through strong ​​intellectual property ​​​​​​frameworks​​ and establishing a public-private dialogue on innovative pharmaceuticals.

We need a clear action plan, not just more legislation, to translate our scientific leadership into tangible health outcomes. ​​We must treat this sector as a pillar of our sovereignty and a strategic asset, not merely a cost to be managed. 

A ​​c​​​​onsequential ​​c​​​​hoice 

Europe has to choose. Either we can continue to approach life science innovation as a budgetary threat, only to reali​​z​​​​e too late that we have weakened our competitiveness and delayed new treatments for patients. Or we can recogni​​z​​​​e innovation for what it is ​​—​​​​ an economic multiplier that strengthens our productivity, resilience​​ and global influence ​​—​​​​ and ensure that Europe remains a place where the next generation of medical breakthroughs is discovered, developed​​ and delivered to patients. 

There is no middle ground. Europe must stop focus​​ing solely on the cost of innovation and start asking how much innovation it can afford to lose. In the global race for talent and capital, hesitation is a decision. The rest of the world is not waiting.

References

1. The value of health: Investing in Europe’s future [EPC 2026]
2. ​​Economic and Societal Footprint of the Pharmaceutical Industry in Europe [VE / PwC 2024]
3. International trade of EU and non-EU countries since 2002 by SITC [Eurostat 2026]
4. The 2025 EU Industrial R&D Investment Scoreboard [EC 2025]

Disclaimer

POLITICAL ADVERTISEMENT

• The sponsor is European Federation of Pharmaceutical Industries and Associations (EFPIA)
• The entity ultimately controlling the sponsor is European Federation of Pharmaceutical Industries and Associations (EFPIA)
• The political advertisement is linked to  EU pharmaceutical regulation and innovation policy.

More information here.